Anti-CD20-based therapy of B cell lymphoma: state of the art

被引：52

作者：

Kosmas, C

Stamatopoulos, K

Stavroyianni, N

Tsavaris, N

Papadaki, T

机构：

[1] Metaxa Canc Hosp, Div Med Oncol 2, Dept Med, Piraeus, Greece

[2] G Papanicolaou Gen Hosp, Dept Hematol, Thessaloniki, Greece

[3] Univ Athens, Sch Med, Dept Pathophysiol, Oncol Unit,Laikon Gen Hosp, GR-11527 Athens, Greece

[4] Evangelismos Med Ctr, Hemopathol Dept, Athens, Greece

来源：

LEUKEMIA | 2002年 / 16卷 / 10期

关键词：

monoclonal antibodies; B cell lymphoma; rituximab; tositumomab; ibritumomab;

D O I：

10.1038/sj.leu.2402639

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the last 5 years, studies applying the chimeric anti-CD20 MAb have renewed enthusiasm and triggered world-wide application of anti-CD20 MAb-based therapies in B cell non-Hodgkin's lymphoma (NHL). Native chimeric anti-CD20 and isotope-labeled murine anti-CD20 MAbs are currently employed with encouraging results as monotherapy or in combination with conventional chemotherapy and in consolidation of remission after treatments with curative intent (ie after/ in combination with high-dose chemotherapy and hematopoietic stem cell rescue). On the available experience, anti-CD20 MAb-based therapeutic strategies will be increasingly integrated in the treatment of B cell NHL and related malignancies.

引用

页码：2004 / 2015

页数：12

共 112 条

[1] EXPRESSION OF HUMAN B CELL-ASSOCIATED ANTIGENS ON LEUKEMIAS AND LYMPHOMAS - A MODEL OF HUMAN B-CELL DIFFERENTIATION [J].

ANDERSON, KC ;

BATES, MP ;

SLAUGHENHOUPT, BL ;

PINKUS, GS ;

SCHLOSSMAN, SF ;

NADLER, LM .

BLOOD, 1984, 63 (06) :1424-1433

[2]

Bennett JM, 2001, BLOOD, V98, p335A

[3]

Berinstein NL, 2002, BONE MARROW TRANSPL, V29, pS14, DOI 10.1038/sj.bmt.1703297

[4] TRANSFECTION OF THE CD20 CELL-SURFACE MOLECULE INTO ECTOPIC CELL-TYPES GENERATES A CA2+ CONDUCTANCE FOUND CONSTITUTIVELY IN B-LYMPHOCYTES [J].

BUBIEN, JK ;

ZHOU, LJ ;

BELL, PD ;

FRIZZELL, RA ;

TEDDER, TF .

JOURNAL OF CELL BIOLOGY, 1993, 121 (05) :1121-1132

[5]

Buckstein R, 1999, SEMIN ONCOL, V26, P115

[6]

Buckstein RJ, 2001, BLOOD, V98, p680A

[7] Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity [J].

Byrd, JC ;

Murphy, T ;

Howard, RS ;

Lucas, MS ;

Goodrich, A ;

Park, K ;

Pearson, M ;

Waselenko, JK ;

Ling, G ;

Grever, MR ;

Grillo-Lopez, AJ ;

Rosenberg, J ;

Kunkel, L ;

Flinn, IW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2153-2164

[8] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[9]

Coiffier B, 1998, BLOOD, V92, P1927

[10] Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation [J].

Colombat, P ;

Salles, G ;

Brousse, N ;

Eftekhari, P ;

Soubeyran, P ;

Delwail, V ;

Deconinck, E ;

Haïoun, C ;

Foussard, C ;

Sebban, C ;

Stamatoullas, A ;

Milpied, N ;

Boué, F ;

Taillan, B ;

Lederlin, P ;

Najman, A ;

Thièblemont, C ;

Montestruc, F ;

Mathieu-Boué, A ;

Benzohra, A ;

Solal-Céligny, P .

BLOOD, 2001, 97 (01) :101-106

← 1 2 3 4 5 6 7 8 9 10 →